COMBINED TOPICAL MINOXIDIL AND FINASTERIDE THERAPY IN ANDROGENETIC ALOPECIA – NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5804Keywords:
Alopecia, Topical, Finasteride, Minoxidil, Dihydrotestosterone, HairAbstract
Background Androgenetic alopecia is a chronic progressive disorder characterized by androgen-dependent miniaturization of hair follicles mediated by dihydrotestosterone. Pharmacological management is based primarily on follicular stimulation with topical Minoxidil and inhibition of 5-α-reductase using Finasteride. Because systemic finasteride may be associated with hormonal exposure, interest has shifted toward topical formulations and combined topical therapy.
Aim The aim of this study was to evaluate recent clinical evidence regarding the efficacy and safety of concurrent topical minoxidil and topical finasteride therapy in patients with androgenetic alopecia.
Material and Methods A narrative literature review was performed using the PubMed database. Publications from 1 January 2019 onward were considered. A broad search combining terms related to alopecia, minoxidil and finasteride identified 261 records. After restricting the results to human clinical comparative or interventional studies and excluding review papers, meta-analyses and case reports, 19 records remained. Application of topical-administration criteria yielded 14 candidate publications. Following manual full-text analysis and exclusion of studies not employing simultaneous topical minoxidil and topical finasteride therapy, 5 studies fulfilled the eligibility criteria and were included in the qualitative synthesis.
Results The included studies demonstrated improved hair density and clinical scalp appearance with combination therapy compared with minoxidil monotherapy. Topical finasteride provided local anti-androgenic activity while systemic exposure remained minimal. Reported adverse effects were uncommon and limited mainly to mild local irritation.
Conclusions Combined topical minoxidil and topical finasteride therapy appears to improve treatment effectiveness while maintaining a favorable safety profile. Larger and longer-term controlled studies are required to determine durability of treatment effects and optimal dosing regimens.
References
Rossi, A., & Caro, G. (2023). Topical finasteride in androgenetic alopecia. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15953
Asad, N., Naseer, M., & Ghafoor, R. (2024). Efficacy of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in treatment of male pattern androgenic alopecia. Journal of Drugs in Dermatology. https://jddonline.com/articles/efficacy-of-topical-finasteride-025-with-minoxidil-5-versus-topical-minoxidil-5-alone-in-treatment-of-male-pattern-androgenic-alopecia-S1545961624P7826X/
Lubis, F. F., Lagiawati, L., Saulina, M., & Saldi, S. R. F. (2024). Topical finasteride therapy in androgenetic alopecia. Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-04216-9
Abeck, F., Hansen, I., Kött, J., Schröder, F., Garrahy, E., Veneroso, J., Rünger, A., Torster, L., Schneider, S. W., & von Büren, J. (2023). Topical finasteride for androgenetic alopecia: Clinical evaluation. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16360
Li, Y., Yu, B., Niu, S., Ding, Z., Gu, Q., Zhang, H., Ding, R., Zhou, C., Men, F., Liu, Y., Zhao, W., Chen, L., Li, S., Wang, Q., Xiao, M., Huang, F., Hu, B., Zhang, J., Zhang, J., & Fang, Y. (2025). Pharmacokinetics and safety of topical finasteride in androgenetic alopecia. Clinical and Experimental Dermatology. https://doi.org/10.1080/09546634.2026.2616198
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jakub Polczyk, Wojciech Deptuch, Paweł Krzysztof Moćko, Zofia Golińska, Maciej Tomasz Zając, Krzysztof Drelich, Przemysław Rajzer, Julia Rurkowska, Filip Ogorzałek, Wiktor Szczuciński
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
